Vertex (VRTX) Pops Higher, Enters Two New HCV Treatment Collaborations
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Join SI Premium – FREE
Vertex Pharmaceuticals (Nasdaq: VRTX) shares are popping higher on the session following two news updates from the company on hepatitis C virus treatment development.
First, Vertex announced that it entered into a non-exclusive agreement with GlaxoSmithKline (NYSE: GSK) to conduct a Phase 2 proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and GSK’s NS5A inhibitor GSK2336805. Vertex and GSK plan to initiate the study in early 2013, pending discussions with regulatory authorities.
For more from the release, click here.
Also, Vertex said it entered into a non-exclusive collaboration with Janssen Pharmaceuticals, Inc. -- o f Johnson & Johnson (NYSE: JNJ) -- to conduct a Phase 2 proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and Janssen’s protease inhibitor simeprevir (TMC435). As part of the collaboration, Janssen will conduct a drug-drug interaction study with VX-135 and simeprevir to support the planned initiation of a Phase 2 proof-of-concept study in early 2013, pending discussions with regulatory authorities.
click here for the full release.
Shares are up over 7 percent on the session Thursday.
First, Vertex announced that it entered into a non-exclusive agreement with GlaxoSmithKline (NYSE: GSK) to conduct a Phase 2 proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and GSK’s NS5A inhibitor GSK2336805. Vertex and GSK plan to initiate the study in early 2013, pending discussions with regulatory authorities.
For more from the release, click here.
Also, Vertex said it entered into a non-exclusive collaboration with Janssen Pharmaceuticals, Inc. -- o f Johnson & Johnson (NYSE: JNJ) -- to conduct a Phase 2 proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and Janssen’s protease inhibitor simeprevir (TMC435). As part of the collaboration, Janssen will conduct a drug-drug interaction study with VX-135 and simeprevir to support the planned initiation of a Phase 2 proof-of-concept study in early 2013, pending discussions with regulatory authorities.
click here for the full release.
Shares are up over 7 percent on the session Thursday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA expands Casgevy approval to children as young as 2
- FDA: classifies Insulet OmniPod pods recall as Class I due to serious injury risk
- VivoPower shifts focus to AI data centers, revises unit spinoff plans
Create E-mail Alert Related Categories
Corporate News, FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
